Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Lean, healthy, non-diabetic male.~Exclusion Criteria:~* Family history of diabetes, BMI over 25.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Pasireotide 600 µg sc bid (Type: EXPERIMENTAL): n=19. Pasireotide 600 µg sc bid
- Pasireotide 900 µg sc bid (Type: EXPERIMENTAL): n=19. Pasireotide 900 µg sc bid
- Pasireotide 1200 µg sc bid (Type: EXPERIMENTAL): n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).